Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- In Shocking U-Turn, Biogen/Eisai Say to File Aducanumab in Early Next Year
October 23, 2019
- Parexel Looks to Set Itself Apart from Rivals through Consulting Services
October 23, 2019
- Sumitomo Dainippon Lifts Q2 Earnings Guidance on Solid Sales in Japan, US, China
October 23, 2019
- European Panel Snubs Daiichi Sankyo’s Quizartinib
October 21, 2019
- JAK Debuts Draw Near in Japan Atopic Dermatitis Market, 1st Likely to Get Listing Next Spring
October 21, 2019
- FDA OKs Xofluza for Flu Patients Carrying High Complication Risks
October 21, 2019
- Shionogi, Janssen, Alzheimer’s Drug Discovery Foundation Join Forces to Develop AD Biomarkers
October 21, 2019
- Kyowa Kirin Recalling Mitomycin over Unauthorized Manufacturing Method, Supply Won’t Resume until 2021
October 18, 2019
- US FDA Panel Backs Shionogi’s Novel Antibiotic
October 18, 2019
- Sumitomo Dainippon Drops Bid to Buy Cynata
October 18, 2019
- FDA Gives Priority Status to Daiichi Sankyo/AZ’s HER2-Tageting ADC
October 18, 2019
- Ranitidine Compensation Programs Draw Complaints from Pharmacists, Separate Billing Seen “Unrealistic”
October 17, 2019
- Xofluza Filed in Japan for Post-Exposure Prophylaxis
October 17, 2019
- Asahi Kasei Initiates Voluntary Recall of Nafamostat after Glass Fragment Found in Vial
October 17, 2019
- Takeda to Divest 30 OTC, Non-Core Assets to Swiss Firm
October 16, 2019
- Astellas to Sell 3 Asian Products to Daiichi Sankyo for 9.6 Billion Yen
October 16, 2019
- FDA OKs 1st Schizophrenia Patch Drug: Hisamitsu
October 16, 2019
- Eisai’s Fycompa Gets China Thumbs-Up
October 16, 2019
- No Major Drug Supply Disruption after Typhoon Hagibis
October 16, 2019
- Sakigake-Designated Radiation Therapy Agent Filed in Japan
October 16, 2019
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…